糖心视频

, the life science arm of , has raised $1 billion in a mega-round led by . The private equity giant took a stake in Verily as part of the funding, according to the company.

Other new investors in the round include and other unnamed global investment management firms, according to a issued Thursday afternoon by Verily.

Follow Crunchbase News on

Also as part of the financing, Alphabet CFO and , managing partner and managing director of Silver Lake, will join Verily鈥檚 operating board.

The funding brings South San Francisco-based Verily鈥檚 total raised to , according to its Crunchbase profile. Its last raise was in January 2017 when Singapore鈥檚 put $800 million in the company formerly known as Google Life.

In the release, Verily CEO said the money will be used to 鈥渟upport growth in key strategic areas, including investments in strategic partnerships, global business development opportunities, and potential acquisitions.鈥� The company declined to provide further details.

Verily is “creating the building blocks for broadly useful health platforms, starting with targeted efforts in diseases that affect large populations such as diabetes,” according to Carolyn Wang, head of communications for the firm. Among its initiatives is the launch of聽聽a joint venture with Sanofi that offers a virtual care platform with novel technology for people with Type 2 diabetes, according to Wang. Verily also聽has been to develop the world鈥檚 smallest continuous glucose meter for people with diabetes.

Besides diabetes, the 700-person company is focused on addressing such as deteriorating vision, multiple sclerosis, and Parkinson鈥檚 disease. It also is working on disease detection. It recently announced it would have to on its glucose monitoring, smart contact lens project due to from human tears.

The life science sector is not for the faint of heart, or for those who lack patience, due to its long cycles and risks for failure. But clearly, investors are willing to place bets in the sector. In December, Jason Rowley and I wrote about how IPO was expected to start trading in what is being touted as one the largest U.S. biotech IPOs ever.

Illustration:

Note: This article was updated post-publication to include information provided directly from Verily.